<DOC>
	<DOCNO>NCT01598051</DOCNO>
	<brief_summary>The objective study understand Rivaroxaban improve treatment satisfaction Warfarin patient assess safety effectiveness Xarelto real clinical practice . A total 725 patient enrol follow 6 months.period . QOL survey conduct month 0 , 3 , 6 use ACTS/TSQM . This study categorize regulatory post-marketing surveillance Japan , local prospective observational study patient receive Xarelto SPAF .</brief_summary>
	<brief_title>Xarelto SPAF-QOL Post-marketing Surveillance Japan</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Brain Ischemia</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Patients treat Warfarin atrial fibrillation least two month time study initiation . Rivaroxaban na√Øve patient Patients 20 year old old . Patients agree sign inform consent Patients contraindicate product label</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Xarelto</keyword>
	<keyword>SPAF</keyword>
	<keyword>QOL</keyword>
</DOC>